The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of pazopanib in combination with interferon alfa in patients with advanced renal cell carcinoma (RCC) and other primary tumors: A Spanish Oncology Genitourinary Group (SOGUG) study.
Xavier Garcia del Muro
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Ignacio Duran
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jesús García-Donas
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Juan Francisco Rodriguez-Moreno
No relevant relationships to disclose
Marta Gil-Martin
No relevant relationships to disclose